Free tool
FAERS Monitor: Marplan
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 011961 or its brand name (Marplan, Isocarboxazid). Reports on generic versions are filed under their own applications.
Reports
94
Serious
61
65% of reports
Hospitalization
27
Death reported
21
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- completed suicide17
- drug ineffective14
- insomnia10
- toxicity to various agents10
- dizziness7
- serotonin syndrome7
- stress cardiomyopathy7
- malaise6
- depression5
- headache5
- hyperhidrosis5
- vision blurred5
- weight increased5
- blood pressure increased4
- confusional state4
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2009 | 3 |
| 2010 | 5 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 4 |
| 2014 | 4 |
| 2015 | 5 |
| 2016 | 6 |
| 2017 | 12 |
| 2018 | 10 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 3 |
| 2025 | 1 |
| 2026 | 24 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,065 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| stress cardiomyopathySignal | 7 | 269.7 | 132.2 | 1,613 |
| serotonin syndromeSignal | 7 | 81.6 | 40.0 | 480 |
| completed suicideSignal | 17 | 45.7 | 29.7 | 701 |
| toxicity to various agentsSignal | 10 | 13.3 | 7.4 | 102 |
| hyperhidrosisSignal | 5 | 8.7 | 3.7 | 27 |
| insomniaSignal | 10 | 8.4 | 4.7 | 59 |
| vision blurredSignal | 5 | 8.1 | 3.5 | 25 |
| blood pressure increasedSignal | 4 | 5.9 | 2.2 | 12 |
| confusional stateSignal | 4 | 5.5 | 2.1 | 11 |
| weight increasedSignal | 5 | 5.0 | 2.1 | 12 |
| depressionSignal | 5 | 4.9 | 2.1 | 12 |
| dizzinessSignal | 7 | 3.1 | 1.5 | 8 |
| malaiseSignal | 6 | 3.1 | 1.4 | 7 |
| drug ineffectiveSignal | 14 | 2.4 | 1.5 | 10 |
| headache | 5 | 1.8 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.